The greater cause for concern is the fact that the whistleblower submitted a report to the FDA which was ignored, and was then fired in retaliation. That suggests the possible presence of systemic weaknesses with much broader impact beyond Ventavia.
The inability to swab 477 trial participants to test for SARS-CoV-2 infection is also pretty bad given that confirmed symptomatic cases of COVID were the metric used to establish the efficacy numbers in the trial.